| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. The current knowledge regarding regulation of proglucagon gene expression in the gut and in the brain and mechanisms responsible for the posttranslational processing are reviewed. GLP-1 is released in response to meal intake, and the stimuli and molecular mechanisms involved are discussed. GLP-1 is extremely rapidly metabolized and inactivated by the enzyme dipeptidyl peptidase IV even before the hormone has left the gut, raising the possibility that the actions of GLP-1 are transmitted via sensory neurons in the intestine and the liver expressing the GLP-1 receptor. Because of this, it is important to distinguish between measurements of the intact hormone (responsible for endocrine actions) or the sum of the intact hormone and its metabolites, reflecting the total L-cell secretion and therefore also the possible neural actions. The main actions of GLP-1 are to stimulate insulin secretion (i.e., to act as an incretin hormone) and to inhibit glucagon secretion, thereby contributing to limit postprandial glucose excursions. It also inhibits gastrointestinal motility and secretion and thus acts as an enterogastrone and part of the "ileal brake" mechanism. GLP-1 also appears to be a physiological regulator of appetite and food intake. Because of these actions, GLP-1 or GLP-1 receptor agonists are currently being evaluated for the therapy of type 2 diabetes. Decreased secretion of GLP-1 may contribute to the development of obesity, and exaggerated secretion may be responsible for postprandial reactive hypoglycemia.
This article has been cited by other articles:
|
|
 |
|
  J. Wang, Y. Wang, X. Li, J. Li, and F. C. Leung Cloning, Tissue Distribution, and Functional Characterization of Chicken Glucagon Receptor Poult. Sci., December 1, 2008; 87(12): 2678 - 2688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Knauf, P. D. Cani, D.-H. Kim, M. A. Iglesias, C. Chabo, A. Waget, A. Colom, S. Rastrelli, N. M. Delzenne, D. J. Drucker, et al. Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing Diabetes, October 1, 2008; 57(10): 2603 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cabou, G. Campistron, N. Marsollier, C. Leloup, C. Cruciani-Guglielmacci, L. Penicaud, D. J. Drucker, C. Magnan, and R. Burcelin Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity Diabetes, October 1, 2008; 57(10): 2577 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Hausenloy and D. M. Yellon GLP-1 Therapy: Beyond Glucose Control Circ Heart Fail, September 1, 2008; 1(3): 147 - 149. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tornehave, P. Kristensen, J. Romer, L. B. Knudsen, and R. S. Heller Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas J. Histochem. Cytochem., September 1, 2008; 56(9): 841 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Laferrere, J. Teixeira, J. McGinty, H. Tran, J. R. Egger, A. Colarusso, B. Kovack, B. Bawa, N. Koshy, H. Lee, et al. Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2479 - 2485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Begriche, P. Letteron, A. Abbey-Toby, N. Vadrot, M.-A. Robin, A. Bado, D. Pessayre, and B. Fromenty Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E939 - E951. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
